MiMedx Execs To Pay SEC Nearly $2M To End Fraud Claims
Two convicted former executives of skin graft biotechnology company MiMedx have agreed to pay nearly $2 million to the U.S. Securities and Exchange Commission to resolve claims they played a role...To view the full article, register now.
Already a subscriber? Click here to view full article